Article
NRAS Status Determines Sensitivity to SHP2 Inhibitor Combination Therapies Targeting the RAS-MAPK Pathway in Neuroblastoma.
Cancer research - 15 Aug 2020
Valencia-Sama Ivette, Ladumor Yagnesh, Kee Lynn, Adderley Teresa, Christopher Gabriella, Robinson Claire M, Kano Yoshihito, Ohh Michael, Irwin Meredith S
Abstract excerpt
Survival for high-risk neuroblastoma remains poor and treatment for relapsed disease rarely leads to long-term cures. Large sequencing studies of neuroblastoma tumors from diagnosis have not identified common targetable driver mutations other than the 10% of tumors that harbor mutations in the anaplastic lymphoma kinase (ALK) gene. However, at neuroblastoma recurrence, more frequent mutations in genes in the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.